Does Gemfibrozil Interact with Pitavastatin Calcium?
CDI records a major classification for Gemfibrozil and Pitavastatin Calcium. The stored summary is: Gemfibrozil increases the risk of myopathy and rhabdomyolysis when used concomitantly with pitavastatin. Concomitant use should be avoided. The mechanism involves fibrate-statin interaction increasing myopathy risk. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Gemfibrozil Class
- Peroxisome Proliferator Receptor alpha Agonist
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Fibrate-statin interaction increasing myopathy risk
What To Tell Your Doctor or Pharmacist
If you are taking Gemfibrozil and your doctor is considering prescribing Pitavastatin Calcium (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider